Supplemental arginine and high-dose folate may promote bone health by supporting the activity of endothelial-type nitric oxide synthase in bone.
The endothelial isoform of NO synthase promotes maintenance of bone density by stimulating osteoblastic activity while inhibiting bone catabolism; it appears to be a key mediator of the anabolic effects of mechanical loading, estrogens, and statin therapy on bone. This enzyme is susceptible to competitive inhibition by elevated systemic levels of asymmetric dimethylarginine (ADMA) encountered in vascular disorders associated with endotheliopathy; it may not be coincidental that reduced bone density has been observed in subjects afflicted with many of these disorders. Supplemental arginine has the potential to offset this adverse effect of ADMA. Superoxide production by osteoclasts may also impair bone NO synthase activity by oxidizing its cofactor tetrahydrobiopterin; high-dose folate has been shown to compensate for endothelial deficiency of this cofactor by effectively "pinch hitting" for it. These considerations suggest that supplementation with arginine as well as high-dose folate might aid maintenance of bone density by helping to preserve optimal NO synthase activity in bone cells.
McCarty
Mark F
MF
Pantox Laboratories, 4622 Santa Fe St., San Diego, CA 92109, USA. mccarty@pantox.com
D001120:Arginine / Q000008:administration & dosage* / Q000494:pharmacology; D001842:Bone and Bones / Q000187:drug effects* / Q000201:enzymology / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005492:Folic Acid / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D019001:Nitric Oxide Synthase / Q000378:metabolism*; D052250:Nitric Oxide Synthase Type III
D005492:Folic Acid; D001120:Arginine; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III